SCHEDULE 13G: Soleus Capital Master Fund Discloses 6.3% Passive Stake in Mural Oncology PLC
Beneficial Ownership Report
Soleus Capital Master Fund, along with its affiliated entities and Guy Levy, has reported a passive beneficial ownership of 6.3% in Mural Oncology PLC.
Summary
- Soleus Capital Master Fund, L.P. and its related entities (Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC) and Guy Levy collectively reported beneficial ownership of 1,079,927 ordinary shares of Mural Oncology PLC.
- This aggregate amount represents 6.3% of Mural Oncology PLC's ordinary shares outstanding.
- The percentage is calculated based on 17,228,291 ordinary shares outstanding as of February 28, 2025, as reported in Mural Oncology plc's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The reporting persons have shared voting and shared dispositive power over all 1,079,927 shares.
- The filing explicitly states that the shares were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive beneficial ownership stake. It contains no positive or negative operational news, financial results, or strategic updates from the issuer, thus maintaining a neutral sentiment.
Positives
- The disclosure of a significant stake by an institutional investor like Soleus Capital Master Fund could be viewed as a vote of confidence in Mural Oncology PLC.
- Increased institutional ownership can sometimes lead to greater market liquidity and investor interest.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Mural Oncology PLC's future operations or financial performance. It solely reports a beneficial ownership stake.
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment fund in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment fund has chosen to invest in Mural Oncology PLC.
Stakeholder Impact
- Shareholders: Provides transparency regarding a new significant institutional investor in the company, potentially signaling increased institutional interest.
- Company Management: Informs management of a new substantial shareholder, though the filing indicates a passive investment intent.
Key Dates
| Date | Description |
|---|---|
| February 28, 2025 | Date as of which 17,228,291 ordinary shares of Mural Oncology plc were reported outstanding, used for percentage calculation. |
| April 15, 2025 | Date of event which required the filing of this statement. |
| April 16, 2025 | Date the Schedule 13G was signed and filed. |
Keywords
Mural Oncology PLC, Soleus Capital Master Fund, Schedule 13G, Beneficial Ownership, Institutional Investor, Equity Stake, Passive Investment, G63365103
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.